Novel nanotherapy breakthrough may help reduce recurrent heart attacks and stroke

Novel nanotherapy breakthrough may help reduce recurrent heart attacks and stroke
Mount Sinai's novel HDL nanoparticle (red), loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels.

(Medical Xpress)—Up to 30 percent of heart attack patients suffer a new heart attack because cardiologists are unable to control inflammation inside heart arteries—the process that leads to clots rupturing and causing myocardial infarction or stroke.

But a report in Nature Communications by Icahn School of Medicine at Mount Sinai scientists showcases the development of a new technology that may provide a solution to this high risk of repeat heart attacks—and potentially help save more lives.

An international research team, led by Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a . In mouse studies, they show this HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels.

Not only could the HDL nanotherapy potentially avert repeat heart attacks, it may also have the power to reduce recurrent strokes caused by clots in brain arteries, says the study's senior investigator, Willem Mulder, PhD, Associate Professor of Radiology in the Translational and Molecular Imaging Institute at the Icahn School of Medicine at Mount Sinai.

"We envision that a safe and effective HDL nanotherapy could substantially lower cardiovascular events during the critical period of vulnerability after a heart attack or stroke," says Dr. Mulder.

"While we have much more to do to confirm clinical benefit in patients, our study shows how this nanotherapy functions biologically, and how this novel concept could potentially also work in the clinical setting to solve a critical problem," says Dr. Mulder. "This nanotherapy would be the first of its kind."

Inject HDL Statin Nanotherapy Right After Heart Attack and Stroke Treatment

The research team, led by two PhD graduate students as first authors—Raphael Duivenvoorden, MD, and Jun Tang, MS— fashioned the nanoparticle to resemble an HDL cholesterol particle. In fact, the nanoparticle binds on to the same receptors as natural HDL in order to deliver the statin drug.

Oral statin medications used by millions of people today work primarily in the liver to reduce levels of unhealthy lipids, such as low density lipoproteins (LDL), that circulate in the blood. Statins also exert a very weak dampening effect on some inflammatory cells, foremost those called macrophages that hide within plaque in the arterial walls.

It is this anti-inflammatory function that the researchers sought to bolster by designing their HDL nanotherapy.

Inflammation is the main driver of plaque buildup in arteries. Without inflammation, as well as lipid deposition in blood vessels, clots would not form. As inflammation progresses, macrophages secrete enzymes that degrade the walls of blood vessels, leading to a break in the vessel and the formation of clots. These clots can then clog arteries, leading to a heart attack or stroke.

"Levels of inflammation spike after a heart attack, which is why up to 30 percent of may suffer another heart attack, some while in hospital or just after discharge," says co-author Zahi Fayad, PhD, Professor of Radiology and Director of the Translational and Molecular Imaging Institute at Icahn School of Medicine at Mount Sinai. "This is the vital time to attack this inflammation culprit, which we currently are unable to do clinically right now," says Dr. Fayad. "Even with the most aggressive treatment available, repeat heart attacks do occur."

According to Mount Sinai researchers, the best way to use their HDL nanotherapy is by injection after the clot that produces a heart attack or stroke has been treated. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response. "This could potentially and very rapidly stabilize a dangerous situation," Dr. Mulder says. "In addition, after discharge, patients would continue to use their oral statins to control LDL in their blood."

"Our study also confirms that the HDL nanoparticle is not seen as a foreign invader by the body's immune system and that it has an inherent and natural affinity to target plaque macrophages," says Jun Tang. "Our experiments demonstrated a very rapid reduction in inflammation in mice with advanced plaque buildup."

If the HDL nanotherapy works well in clinical studies, it may be possible to use it in the future as a prevention tool, according to Dr. Fayad. "If proven to be safe and effective in humans, this would be a critical advance for cardiovascular medicine. We look forward to further testing of our team's novel nanotherapy breakthrough."

More information: "A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation." Raphaël Duivenvoorden, Jun Tang, David P. Cormode, et al. Nature Communications 5, Article number: 3065 DOI: 10.1038/ncomms4065 Received 07 April 2013 Accepted 04 December 2013 Published 20 January 2014

Related Stories

Low HDL-cholesterol—Not quantity, but quality

Apr 30, 2013

Many of the genes regulating the inflammation and immune response of the body are also associated with low HDL-cholesterol levels in the circulation, tells the recent study conducted at the University of ...

Recommended for you

Time to take notice and tackle heart failure

23 minutes ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

3 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments